Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
- 31 August 2006
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 28 (8), 1184-1198
- https://doi.org/10.1016/j.clinthera.2006.08.016
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- LinezolidPharmacoEconomics, 2005
- National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004American Journal of Infection Control, 2004
- Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literatureBMJ, 2004
- Regional variation in the treatment and outcomes of myocardial infarction: investigating New England’s advantageAmerican Heart Journal, 2003
- Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III StudiesAntimicrobial Agents and Chemotherapy, 2003
- Safety and tolerability of linezolidJournal of Antimicrobial Chemotherapy, 2003
- Hematologic Effects of Linezolid: Summary of Clinical ExperienceAntimicrobial Agents and Chemotherapy, 2002
- Nosocomial infections in medical intensive care units in the United StatesCritical Care Medicine, 1999
- The Economic Impact ofStaphylococcus aureusInfection in New York City HospitalsEmerging Infectious Diseases, 1999
- From cost–effectiveness ratios to resource allocation: where to draw the line?Published by Cambridge University Press (CUP) ,1995